{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-037111","form_type":"8-K","ticker":"OABI","cik":"0001846253","company_name":"OmniAb, Inc.","filed_at":"2022-03-23T23:59:59+00:00","discovered_at":"2026-05-14T18:04:08.816594+00:00","generated_at":"2026-06-26T20:03:19.040296+00:00","sec_items":["8.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"APAC to merge with Ligand's OmniAb antibody discovery business at $850M valuation","bullets":["Pre-money equity valuation of $850M; minimum $130M gross cash to combined company, up to $266M.","Avista commits up to $115M ($15M PIPE + $100M backstop); Ligand contributes $15M.","Ligand shareholders to own 75-84% of combined firm; APAC shareholders ~20%, Avista ~5%.","Transaction expected to close H2 2022; OmniAb to list on Nasdaq as 'OABI'.","Matt Foehr named CEO of OmniAb; Kurt Gustafson appointed CFO."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-037111","json":"https://secwatch.observer/filing/0001104659-22-037111.json","markdown":"https://secwatch.observer/filing/0001104659-22-037111.md","text":"https://secwatch.observer/filing/0001104659-22-037111.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1846253/000110465922037111/0001104659-22-037111-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1846253/000110465922037111/tm2210239d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T20:03:19.040296+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}